Tien Laboratory

Researcher holding a bottle of liquid in the lab

About

We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.

Current Research

Some of the ongoing projects are focused on addressing following:

  1. Biomarker and genomic analyses with next generation sequencing (IvySeq) to provide personalized enrollment recommendation.
  2. Pharmacodynamic analysis to assess treatment response and target modulation.
  3. Understanding resistance mechanisms of targeted inhibitors underlying disease progression.

Lab Members

Headshot of Siddhi Desai Read Bio

Siddhi Desai, PhDPostdoctoral Fellow

Hualin Zhang, PhD Read Bio

Hualin Zhang, PhDPostdoctoral Fellow

Inad Rabadi Read Bio

Inad RabadiResearch Technician

Resources

brainrnaseq.org

gliovis.bioinfo.cnio.es

portal.brain-map.org

antibodyregistry.org

biorxiv.org

clinicaltrials.gov

cancer.sanger.ac.uk/cosmic

JOB OPENINGS


Pharmacodynamics Technologist

The Ivy Brain Tumor Center is a non-conventional non-profit program offering state-of-the-art clinical trials for patients with the most aggressive form of brain cancer. It is home to the largest collection of Phase 0 trials for brain tumors in the world. Our multidisciplinary team of brain tumor specialists and scientists are accelerating drug discovery and precision medicine in neuro-oncology in an effort to identify the most promising first-in-class therapies for brain tumor patients.

Candidates with experience in preclinical studies are desirable. Prior experience in conducting molecular biology or genetic aassays and knowledge of signal transduction and oncogenic pathways is preferred.